Both clinical studies were published in medical journal Pharmacology and Pharmacy. The first clinical study was published in the special edition on
Advances in Antiviral Drugs.
The first study concluded: "... the clinical study showed that Gene-Eden-VIR is a safe and effective treatment against
the Human Papillomavirus (HPV) (and other viruses).
Therefore, health care practitioners should recommend Gene-Eden-VIR as a safe and effective antiviral treatment against
These studies provide a scientific proof that Gene-Eden-VIR actually works. To quote from the first study, "this study showed that
the natural product Gene-Eden-VIR safely and effectively decreases symptoms in individuals infected with the HPV (and other viruses)."
Although both studies are written in a language suitable for scientists, you can read them or their abstracts on the home page.
You can also watch Dr. Hanan Polansky, one of the scientists who conducted the study, explains it.
The following information was published by the Centers for Disease Control and Prevention (CDC)
on its website. In brackets and italic letters, you can find
our comments on the CDC information. Also note our yellow highlights.
What is genital HPV infection?
Genital Human Papillomavirus (HPV) is the most common sexually
transmitted infection (STI). The virus infects the skin and mucous
membranes. There are more than 40 HPV types that can infect the
genital areas of men and women, including the skin of the penis, vulva
(area outside the vagina), and anus, and the linings of the vagina,
cervix, and rectum. You cannot see HPV. Most people who become
infected with HPV do not even know they have it.
[The virus in these people is in a latent state.]
What are the symptoms and potential consequences of HPV?
Most people with HPV do not develop symptoms or health problems.
But sometimes, certain types of HPV can cause genital warts in men and
women. Other HPV types can cause cervical cancer and other less common
cancers, such as cancers of the vulva, vagina, anus, and penis. The
types of HPV that can cause genital warts are not the same as the
types that can cause cancer.
Discreet and Confidential
Many people are infected with latent viruses. However, most of them don't want others to know about it.
An infection is a private matter, and most people would like their infection to remain confidential. To protect your privacy, we do the following:
1. Shipping: We will always ship your order in a plain discrete envelope. The envelope has no
external packing list, and no indication of its content.
2. Label: The label on the bottle does not mention the words Herpes, HPV, or any other virus, or disease.
If asked, you can easily and truthfully say that you take Gene-Eden-VIR to boost your immune system.
HPV types are often referred to as "low-risk" (wart-causing) or
"high-risk" (cancer-causing), based on whether they put a person at
risk for cancer. In 90% of cases, the body's immune system clears the
HPV infection naturally within two years. This is true of both
high-risk and low-risk types.
[Note: In 10% of the cases the immune system is too weak to clear the
latent HPV! In these cases, Gene-Eden-VIR can help the immune system clear the latent HPV virus.]
Genital warts usually appear as small bumps or
groups of bumps, usually in the genital area. They can be raised or
flat, single or multiple, small or large, and sometimes cauliflower
shaped. They can appear on the vulva, in or around the vagina or anus,
on the cervix, and on the penis, scrotum, groin, or thigh. Warts may
appear within weeks or months after sexual contact with an infected
person. Or, they may not appear at all. If left untreated, genital
warts may go away, remain unchanged, or increase in size or number.
They will not turn into cancer.
Cervical cancer does not have symptoms until it is
quite advanced. For this reason, it is important for women to get
screened regularly for cervical cancer.
[Screening is very important. However, if you are already infected with the HPV virus,
Gene-Eden-VIR can help your immune system target the latent human papillomavirus.
Scientists at the Center for the Biology of Chronic Disease conducted a
clinical study of Gene-Eden-VIR.
The clinical study showed that Gene-Eden-VIR is safe and effective.
The study concluded: "Our post marketing clinical study showed that
Gene-Eden-VIR is a safe and effective treatment against the Human Papillomavirus (HPV)."
In fact the study showed that Gene-Eden-VIR decreased the duration, severity, and frequency of
symptoms caused by the HPV virus.]
Do you want to help your immune system target the latent HPV virus?
The development of Gene-Eden-VIR was inspired by Dr. Hanan Polansky's research of latent viruses.
Before you buy Gene-Eden-VIR, you might want to read
about Dr. Hanan Polansky and his highly acclaimed scientific
achievements. Just enter his name in Google, and follow the links.
Other less common HPV-related cancers, such as
cancers of the vulva, vagina, anus and penis, also may not have signs
or symptoms until they are advanced.
How do people get genital HPV infections?
Genital HPV is passed on through genital contact, most often during
vaginal and anal sex. A person can have HPV even if years have passed
since he or she had sex. Most infected persons do not realize they are
infected or that they are passing the virus to a sex partner.
Very rarely, a pregnant woman with genital HPV can pass HPV to her
baby during vaginal delivery. In these cases, the child may develop
warts in the throat or voice box - a condition called recurrent
respiratory papillomatosis (RRP).
How does HPV cause genital warts and cancer?
HPV can cause normal cells on infected skin or mucous membranes to
turn abnormal. Most of the time, you cannot see or feel these cell
changes. In most cases, the body fights off HPV naturally and the
infected cells then go back to normal.
Sometimes, low-risk types of HPV can cause visible changes that
take the form of genital warts.
If a high-risk HPV infection is
not cleared by the
immune system, it can linger for many years and turn abnormal cells
into cancer over time. About 10% of women with high-risk HPV on
their cervix will develop long-lasting HPV infections that put them
at risk for cervical cancer. Similarly, when high-risk HPV lingers
and infects the cells of the penis, anus, vulva, or vagina, it can
cause cancer in those areas. But these cancers are much less common
than cervical cancer.
HPV infection. Approximately
20 million Americans
are currently infected with HPV, and another
6.2 million people become
newly infected each year. At least 50% of sexually active men and
women acquire genital HPV infection at some point in their lives.
Genital warts. About 1% of sexually active adults
in the U.S. have genital warts at any one time.
Cervical cancer. The American Cancer Society
estimates that in 2008, 11,070 women will be diagnosed with cervical
cancer in the U.S.
Other HPV-related cancers are much less common
than cervical cancer. The American Cancer Society estimates that in
2008, there will be:
3,460 women diagnosed with vulvar cancer;
2,210 women diagnosed with vaginal and other female genital
1,250 men diagnosed with penile and other male genital cancers;
3,050 women and 2,020 men diagnosed with anal cancer.
Certain populations may be at higher risk for HPV-related cancers,
such as gay and bisexual men, and individuals with weak immune systems
(including those who have HIV/AIDS).
RRP is very rare. It is estimated that less than
2,000 children get RRP every year.
vaccine can now protect females from the four types of HPV that
cause most cervical cancers and genital warts. The vaccine is
recommended for 11 and 12 year-old girls. It is also recommended for
girls and women age 13 through 26 who have not yet been vaccinated or
completed the vaccine series.
For those who choose to be sexually active, condoms may lower the risk
of HPV, if used all the time and the right way. Condoms may also lower
the risk of developing HPV-related diseases, such as genital warts and
cervical cancer. But HPV can infect areas that are not covered by a
condom - so condoms may not fully protect against HPV. So the
only sure way to prevent HPV is to avoid all sexual activity.
Individuals can also lower their chances of getting HPV by being in
a mutually faithful relationship with someone who has had no or few
sex partners. However, even people with only one lifetime sex partner
can get HPV,
if their partner was infected with
HPV. For those who are
not in long-term mutually monogamous relationships, limiting the
number of sex partners and choosing a partner less likely to be
infected may lower the risk of HPV. Partners less likely to be
infected include those who have had no or few prior sex partners.
it may not be possible to determine if a partner who has been sexually
active in the past is currently infected.
How can people prevent HPV-related diseases?
There are important steps girls and women can take to prevent
cervical cancer. The HPV vaccine can protect against
most cervical cancers (see above). Cervical cancer
can also be prevented with routine
cervical cancer screening and follow-up of abnormal results. The
Pap test can identify abnormal or pre-cancerous changes in the cervix
so that they can be removed before cancer develops. An HPV DNA test,
which can find high-risk HPV on a woman's cervix, may also be used
with a Pap test in certain cases. The HPV test can help healthcare
professionals decide if more tests or treatment are needed. Even women
who got the vaccine when they were younger need regular cervical
cancer screening because the vaccine does not protect against all
There is currently no vaccine licensed to prevent HPV-related
diseases in men. Studies are now being done to find out if the vaccine
is also safe in men, and if it can protect them against HPV and
related conditions. The FDA will consider licensing the vaccine for
boys and men if there is proof that it is safe and effective for them.
There is also no approved screening test to find early signs of
penile or anal cancer. Some experts recommend yearly
anal Pap tests for gay and bisexual men and for HIV-positive persons
because anal cancer is more common in these populations. Scientists
are still studying how best to screen for penile and anal cancers in
those who may be at highest risk for those diseases.
Generally, cesarean delivery is not recommended for women with
genital warts to prevent RRP in their babies. This is
because it is unclear whether cesarean delivery actually prevents RRP
in infants and children.
Is there a test for HPV?
The HPV test on the market is only used as part of cervical cancer
screening. There is no general test for men or women to check one's
overall "HPV status. HPV usually goes away on its own, without
causing health problems. So an HPV infection that is found today will
most likely not be there a year or two from now. For this reason,
there is no need to be tested just to find out if you have HPV now.
However, you should get tested for signs of disease that HPV can
cause, such as cervical cancer.
Genital warts are diagnosed by visual
inspection. Some health care providers may use acetic acid, a
vinegar solution, to help identify flat warts. But this is not a
sensitive test so it may wrongly identify normal skin as a wart.
Cervical cell changes (early signs of cervical
cancer)can be identified by routine Pap tests. The
HPV test can identify high-risk HPV types on a woman's cervix, which
can cause cervical cell changes and cancer.
There are treatments for the diseases that HPV can cause:
Visible genital warts can be removed by
patient-applied medications, or by treatments performed by a health
care provider. Some individuals choose to forego treatment to see if
the warts will disappear on their own. No one treatment is better than
Cervical cancer is most treatable when it is
diagnosed and treated early. There are new forms of surgery, radiation
therapy, and chemotherapy available for patients [see
www.cancer.org]. But women who
get routine Pap testing and follow up as needed can identify problems
before cancer develops. Prevention is always better than
Other HPV-related cancers are also more treatable
when diagnosed and treated early. There are new forms of surgery,
radiation therapy, and chemotherapy available for patients. [see
Where can I get more information?
Click on the following more personal questions for their answers.
American Cancer Society. Cancer Facts & Figures, 2008. Atlanta:
American Cancer Society: 2008.
Centers for Disease Control and Prevention. Sexually Transmitted
Diseases Treatment Guidelines 2006. MMWR 2006; 55 [No. RR-11].
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS,
Markowitz LE. Prevalence of HPV infection among females in the United
States. JAMA. 2007;297(8):813-9.
FUTURE II Study Group. Prophylactic efficacy of a quadrivalent
human papillomavirus (HPV) vaccine in women with virological evidence
of HPV infection J Infect Dis. 2007; 196:1438-1446.
FUTURE II Study Group. Quadrivalent vaccine against human
papillomavirus to prevent high-grade cervical lesions. N Engl J Med.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM,
Leodolter S, et al. Females United to Unilaterally Reduce Endo/Ectocervical
Disease (FUTURE) I Investigators. Quadrivalent vaccine against human
papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;
Koutsky LA, Kiviat NB. Genital human papillomavirus. In: K. Holmes,
P. Sparling, P. Mardh et al (eds). Sexually Transmitted Diseases, 3rd
edition. New York: McGraw-Hill, 1999, p. 347-359.
Kiviat NB, Koutsky LA, Paavonen J. Cervical neoplasia and other
STD-related genital tract neoplasias. In: K. Holmes, P. Sparling, P.
Mardh et al (eds). Sexually Transmitted Diseases, 3rd edition. New
York: McGraw-Hill, 1999, p. 811-831.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER.
Quadrivalent human papillomavirus vaccine: Recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR. 2007; 56:
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical
model for the natural history of human papillomavirus infection and
cervical carcinogenesis. American Journal of Epidemiology 2000;
Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et
al. Efficacy of a prophylactic adjuvanted bivalent L1
virus-like-particle vaccine against infection with human
papillomavirus types 16 and 18 in young women: an interim analysis of
a phase III double-blind, randomised controlled trial. Lancet
Weinstock H, Berman S, Cates W. Sexually transmitted disease among
American youth: Incidence and prevalence estimates, 2000.
Perspectives on Sexual and Reproductive Health 2004; 36: 6-10.
Winer R, Hughes JP, Feng Q, et al. Consistent condom use from time
of first vaginal intercourse and the risk of genital human
papillomavirus infection in young women. N Engl J Med.